3 not yet recruiting, 2 completed, 1 active not recruiting, 1 unknown. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Not yet recruiting 2, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Suzhou Sanegene Bio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria SGB-9768 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 24 | 2026-10-31 | 2026-09-04 |
| A Study of SGB-7342 in Subjects With Obesity or Overweight SGB-7342, SGB-7342-Matching placebo - Obesity & Overweight | Phase 1 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 45 | 2026-01-12 | 2026-01-09 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| A Study of SGB-3383 in Healthy Subjects SGB-3383, SGB-3383-Matching placebo - Healthy Volunteers | Phase 1 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 37 | 2025-06-01 | 2025-06-03 |
| Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects SGB-3908, SGB-3908-Matching placebo - Hypertension,Essential | Phase 1 | Completed | Suzhou Sanegene Bio Inc. | 40 | 2024-07-31 | 2026-02-10 |
| A Study of SGB-9768 in Adult Healthy Volunteers SGB-9768, Placebo - Healthy Volunteer | Phase 1 | Completed | Suzhou Sanegene Bio Inc. | 45 | 2024-07-18 | 2026-09-04 |
| A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) SGB-3403, Atorvastatin, Placebo - Hyperlipidemias | Phase 1 | Unknown | Suzhou Sanegene Bio Inc. | 64 | 2024-02-18 | 2024-02-02 |
Essential Hypertension (1) · Glomerulonephritis, IGA (1) · Hemoglobinuria, Paroxysmal (1) · Hyperlipidemias (1) · Obesity (1) · Overweight (1)
Atorvastatin (1)
China (4)